Selected Publications

Pan-RAS Program

Novel RAS Inhibitor, MCI-062, potently and selectively inhibits the growth of KRAS mutant pancreatic tumor cells by blocking GTP loading of RAS. Mattox et al. AACR Annual Meeting 2019. [Download Poster]

Targeting RAS and downstream signaling in high-grade serious ovarian carcinoma with novel RAS inhibitors. Mattox et al. AACR Annual Meeting 2019. [Download Poster] 

A novel RAS Inhibitor, MCI-062, inhibits colon tumor growth in vivo and activates antitumor immunity. Keeton et al. AACR Annual Meeting 2019.  

 

PDE10/β-catenin Program

PDE10 inhibition is associated with reduced colon tumor formation: discovery of a novel PDE10 inhibitor, MCI-030. Ward et al. AACR Annual Meeting 2019. [Download Poster]  

A novel PDE10/beta-catenin inhibitor, MCI-048, suppresses lung tumorigenesis to block metastasis. Zhu et al. AACR Annual Meeting 2019.

Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling. Oncotarget. 2017 Aug 27;8(41):69264-69280.

β-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG. Oncotarget. 2016 Feb 2;7(5):5353-65.    

Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity. 2015 Mar 19;34(12):1499-509.    

Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10. 2015 Sep 29;6(29):27403-15.